Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex

Complement is a central effector system within the immune system and is implicated in a range of inflammatory disorders. CD59 is a key regulator of complement membrane attack complex (MAC) assembly. The atherogenic role of terminal complement has long been suspected but is still unclear. Here, we demonstrate that among mice deficient in apolipoprotein (Apo)E, the additional loss of murine CD59 (mCd59ab−/−/ApoE−/−) accelerated advanced atherosclerosis featuring occlusive coronary atherosclerosis, vulnerable plaque, and premature death and that these effect could be attenuated by overexpression of human CD59 in the endothelium. Complement inhibition using a neutralizing anti-mouse C5 antibody attenuated atherosclerosis in mCd59ab−/−/ApoE−/− mice. Furthermore, MAC mediated endothelial damage and promoted foam cell formation. These combined results highlight the atherogenic role of MAC and the atheroprotective role of CD59 and suggest that inhibition of MAC formation may provide a therapeutic approach for the treatment of atherosclerosis.

[1]  G. Rosoklija,et al.  Local activation of the complement system in endoneurial microvessels of diabetic neuropathy , 2000, Acta Neuropathologica.

[2]  A. Bengtsson,et al.  IgG binding to cytoskeletal intermediate filaments activates the complement cascade. , 1987, Experimental cell research.

[3]  S. Miyagawa.  [Complement regulatory proteins]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[4]  J. Boyle,et al.  Brief Report: Accelerated Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice Lacking the Membrane-Bound Complement Regulator CD59 , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[5]  J. Halperin,et al.  Deficiency of the mouse complement regulatory protein mCd59b results in spontaneous hemolytic anemia with platelet activation and progressive male infertility. , 2003, Immunity.

[6]  Charles Lee,et al.  Genomic structure, functional comparison, and tissue distribution of mouse Cd59a and Cd59b , 2001, Mammalian Genome.

[7]  M. Walport,et al.  Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. , 2001, Blood.

[8]  J. Halperin,et al.  Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. , 1993, The Journal of clinical investigation.

[9]  M. Rynkiewicz,et al.  Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9). , 1993, Blood.

[10]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[11]  T. Badea,et al.  Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. , 1999, Atherosclerosis.

[12]  J. Borén,et al.  Lack of Complement Factor C3, but Not Factor B, Increases Hyperlipidemia and Atherosclerosis in Apolipoprotein E−/− Low-Density Lipoprotein Receptor−/− Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[13]  R. Kinscherf,et al.  Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[14]  F. Netter,et al.  Supplemental References , 2002, We Came Naked and Barefoot.

[15]  A. Goldfine,et al.  Molecular basis for a link between complement and the vascular complications of diabetes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Bronson,et al.  Rapid conditional targeted ablation of cells expressing human CD59 in transgenic mice by intermedilysin , 2008, Nature Medicine.

[17]  T. V. van Berkel,et al.  Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development , 2006, FEBS letters.

[18]  J. Halperin,et al.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells , 1994, The Journal of experimental medicine.

[19]  A. Hays,et al.  Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. , 2004, Diabetes.

[20]  M. Mizuno,et al.  The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility , 2008, Molecular Immunology.

[21]  M. Katerelos,et al.  High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection. , 1998, Transplantation.

[22]  R. Parker,et al.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.

[23]  H. Rus,et al.  Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. , 1985, Immunology letters.

[24]  M. Birnbaum,et al.  Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. , 2007, Cell metabolism.

[25]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[26]  K. Cianflone,et al.  Critical review of acylation-stimulating protein physiology in humans and rodents. , 2003, Biochimica et biophysica acta.

[27]  H. Rus,et al.  Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. , 1986, Atherosclerosis.

[28]  S. Meri,et al.  Regulation of complement membrane attack complex formation in myocardial infarction. , 1993, The American journal of pathology.

[29]  Elias A. Rahal,et al.  Serum C-Reactive Protein and Complement Proteins in Patients with Acute Myocardial Infarction , 2005, Immunopharmacology and immunotoxicology.

[30]  Y. Chao,et al.  ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. , 2001, Biochemical and biophysical research communications.

[31]  D. Accili,et al.  Increased CD36 protein as a response to defective insulin signaling in macrophages. , 2004, The Journal of clinical investigation.

[32]  R. Bronson,et al.  Further Characterization of Reproductive Abnormalities in mCd59b Knockout Mice: A Potential New Function of mCd59 in Male Reproduction1 , 2005, The Journal of Immunology.

[33]  Jason L Johnson,et al.  Characteristics of Intact and Ruptured Atherosclerotic Plaques in Brachiocephalic Arteries of Apolipoprotein E Knockout Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P. Libby,et al.  Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  V. Rus,et al.  C5b-9-induced Endothelial Cell Proliferation and Migration Are Dependent on Akt Inactivation of Forkhead Transcription Factor FOXO1* , 2006, Journal of Biological Chemistry.

[36]  P. Lachmann,et al.  Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[37]  W. Reenstra,et al.  Gastrointestinal Ischemia-Reperfusion Injury Is Lectin Complement Pathway Dependent without Involving C1q 1 , 2005, The Journal of Immunology.

[38]  T. Littlewood,et al.  Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis , 2006, Nature Medicine.

[39]  W. Hu,et al.  Analysis of the promoters and 5′-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes , 2006, Genes and Immunity.

[40]  M. Mizuno,et al.  CD59a Is the Primary Regulator of Membrane Attack Complex Assembly in the Mouse1 , 2004, The Journal of Immunology.

[41]  Shobha Ghosh,et al.  Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. , 2007, The Journal of clinical investigation.

[42]  Gérard J Arlaud,et al.  Modified low density lipoproteins differentially bind and activate the C1 complex of complement. , 2007, Molecular immunology.

[43]  S. Meri,et al.  Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[44]  J. Halperin,et al.  Complement and complement regulatory proteins as potential molecular targets for vascular diseases. , 2004, Current pharmaceutical design.

[45]  Rob Krams,et al.  Assessment of Unstable Atherosclerosis in Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[46]  John D Lambris,et al.  Generation of C5a in the absence of C3: a new complement activation pathway , 2006, Nature Medicine.

[47]  Gongxiong Wu,et al.  Generation and phenotyping of mCd59a and mCd59b double‐knockout mice , 2009, American journal of hematology.

[48]  C. Gerhardinger,et al.  Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. , 2002, Diabetes.